Trial intelligence / Profile preview

Rotigotine in idiopathic restless legs syndrome: multicenter, double-blind, randomized phase 3 trial

2005-002814-39Phase 3Completed

Sponsor
Schwarz Pharma
Start
Oct 2005
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of rotigotine in restless legs syndrome (RLS), sponsored by Schwarz Pharma. Primary endpoint: Periodic limb movement index (PLMI) during time in bed by polysomnography. Started Oct 2005; status: completed.

02

Drugs

rotigotine
03

Conditions

restless legs syndrome (RLS)

Beyond the preview

Go deeper on 2005-002814-39.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-002814-39.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call